FDA Grants Orphan Drug Designation to ENMD-2076 for Hepatocellular Carcinoma
CASI Pharmaceuticals, Inc, announced that its investigational agent ENMD-2076 has received orphan drug designation from the U.S. Food & Drug Administration (FDA) for the treatment of hepatocellular carcinoma. ENMD-2076 is an orally active Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.
The drug has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase, which is a key regulator of mitosis and is often overexpressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3, and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers.
ENMD-2076 previously received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, and acute myeloid leukemia. Phase II studies of ENMD-2076 in ovarian cancer, triple-negative breast cancer, metastatic soft-tissue sarcoma, and advanced ovarian clear cell carcinomas are currently underway.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
